NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

Highlights,Financial firms have revised their evaluations of Regeneron Pharmaceuticals.,The company reported strong earnings, ...

Highlights,Revised valuation estimates from reputable financial sources (NASDAQ:REGN),Strong quarterly earnings with revenue ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Clearly, options traders are pricing in a big move for Regeneron Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Regeneron Pharmaceuticals is a Zacks Rank ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

SAN FRAN­CIS­CO — Just over 20 years ago, the peo­ple of Cal­i­for­nia vot­ed to spend bil­lions of dol­lars on an ex­cit­ing new idea to re­make med­i­cine … ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...

Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to ...